Tecan and Pierce Biotechnology have reached an agreement to develop and co-market a series of high-throughput screening (HTS) solutions offering fluorescence lifetime technology (FLT)
The collaborative effort will use Tecan's Ultra Evolution detection platform for high-throughput fluorescence lifetime measurements and Pierce's HTS assay technologies.
FLT is a highly sensitive spectroscopic technology ideally suited to drug-screening procedures.
By overcoming key bottlenecks associated with HTS assays, such as compound interference and false-positive or negative results, this high-performance solution will deliver significant benefits for compound library screening and lead compound validation.
"The development of an optimised solution for FLT-based assays represents a major advance to fully exploit the potential of Tecan's Ultra Evolution detection platform.
"By working with the leader in assay development, we will be able to provide powerful solutions that address many of the key barriers associated with obtaining quality test results," said Aitor Galdos, chief executive officer of Tecan.
"This collaboration brings together two powerful innovators with strong market positions in their respective fields of reagents and detection technologies," said Leland Foster, president and chief executive officer of Fisher Biochemicals, Pierce's parent organisation.
"The complementary technology platforms will result in assays that will be more sensitive, accurate and robust in the development of new medicines".
As part of the co-marketing agreement, the two companies will share specific product information and support.
Each company will co-promote the other's technologies in sales and marketing literature for their respective technology.
The companies plan to develop a series of scientific application notes that describe challenging or novel applications that can be more easily accomplished or yield better results using the combination of Pierce and Tecan products.
